GlaxoSmithKline makes Quebec the hub of its vaccine research and manufacturing

From the Montreal Gazette:
GlaxoSmithKline Plc, the world's second-biggest biopharma group, said yesterday Quebec will become the hub of its North American vaccine research and manufacturing operations, lifting the province's ambition to become a leader in life sciences.

GSK is investing $50 million of its own money to upgrade and expand its Laval vaccines research labs acquired along with a big Quebec City vaccines manufacturing plant in the $1.7-billion takeover of ID BioMedical in 2005.

"The Laval operation is being designated the North American HQ of our innovative vaccines division, the Belgium-based GSK Biologicals, and the administrative centre," said Paul Lucas, CEO of GlaxoSmithKline Canada, GSK's main Canadian arm based in Mississauga, Ont. ...more